These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Temporally designed treatment of melanoma cells by ATRA and polyI: C results in enhanced chemokine and IFNβ secretion controlled differently by TLR3 and MDA5. Szabo A; Osman RM; Bacskai I; Kumar BV; Agod Z; Lanyi A; Gogolak P; Rajnavolgyi E Melanoma Res; 2012 Oct; 22(5):351-61. PubMed ID: 22797253 [TBL] [Abstract][Full Text] [Related]
24. All-trans retinoic acid synergizes with topotecan to suppress AML cells via promoting RARα-mediated DNA damage. Xu Z; Shao J; Li L; Peng X; Chen M; Li G; Yan H; Yang B; Luo P; He Q BMC Cancer; 2016 Jan; 16():2. PubMed ID: 26728137 [TBL] [Abstract][Full Text] [Related]
25. Differentiation therapy of acute myeloid leukemia: past, present and future. Petrie K; Zelent A; Waxman S Curr Opin Hematol; 2009 Mar; 16(2):84-91. PubMed ID: 19468269 [TBL] [Abstract][Full Text] [Related]
31. Acidic leucine-rich nuclear phosphoprotein 32 family member B (ANP32B) contributes to retinoic acid-induced differentiation of leukemic cells. Yu Y; Shen SM; Zhang FF; Wu ZX; Han B; Wang LS Biochem Biophys Res Commun; 2012 Jul; 423(4):721-5. PubMed ID: 22705300 [TBL] [Abstract][Full Text] [Related]
32. GSK3 is a regulator of RAR-mediated differentiation. Gupta K; Gulen F; Sun L; Aguilera R; Chakrabarti A; Kiselar J; Agarwal MK; Wald DN Leukemia; 2012 Jun; 26(6):1277-85. PubMed ID: 22222598 [TBL] [Abstract][Full Text] [Related]
34. Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals. Hu ZB; Yang GS; Li M; Miyamoto N; Minden MD; McCulloch EA Leukemia; 1995 May; 9(5):789-98. PubMed ID: 7769841 [TBL] [Abstract][Full Text] [Related]
35. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. Fredly H; Reikvam H; Gjertsen BT; Bruserud O Am J Hematol; 2012 Apr; 87(4):368-76. PubMed ID: 22374841 [TBL] [Abstract][Full Text] [Related]
36. Retinoic acid receptor-β gene reexpression and biological activity in SHI-1 cells after combined treatment with 5-aza-2'-deoxycytidine and all-trans retinoic acid. Xiang L; Wang R; Wei J; Qiu G; Cen J; Hu S; Xie X; Chen Z; Gu W Acta Haematol; 2015; 133(3):279-86. PubMed ID: 25413479 [TBL] [Abstract][Full Text] [Related]
37. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Trus MR; Yang L; Suarez Saiz F; Bordeleau L; Jurisica I; Minden MD Leukemia; 2005 Jul; 19(7):1161-8. PubMed ID: 15902297 [TBL] [Abstract][Full Text] [Related]
38. [Effect of translocation t(15;17) on the gene expression regulation of myeloblastin during all trans retinoic acid induced myeloid differentiation in human leukemic cells]. Ballerini P; Besançon F; Cayre YE C R Seances Soc Biol Fil; 1995; 189(4):521-30. PubMed ID: 8564566 [TBL] [Abstract][Full Text] [Related]
39. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter. Tabe Y; Konopleva M; Kondo Y; Contractor R; Jin L; Ruvolo V; Tsutsumi-Ishii Y; Miyake K; Miyake N; Ohsaka A; Nagaoka I; Issa JP; Andreeff M Ann Hematol; 2006 Oct; 85(10):689-704. PubMed ID: 16832676 [TBL] [Abstract][Full Text] [Related]